Home›Companies›Biotech & Pharma›etira

EtiraRX, Inc.

Develops investigational cancer medicines for patients with advanced or metastatic tumors.

Updated Nov 10, 2026·Latest SEC filing May 14, 2026·Suggest an edit

About etira

etira is a private company based in Dallas, Texas. It has reported $9,497,660 raised in three offerings on Form D since October 2023. Its chief executive is Russell Hayward.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Apr 17, 2026May 14, 2026$2,277,533of $3.0M target21$108KEquityRule 506(b)Form D ↗
Jun 6, 2025Jun 23, 2025$2,399,987of $4.8M target3$799KEquityRule 506(b)Form D ↗
Sep 15, 2023Oct 5, 2023$4,820,140of $10.5M target34$141KEquityRule 506(b)Form D ↗
Total, three offerings$9,497,660

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on etira's Form D filed May 14, 2026.

RH
Russell Hayward
Chief Executive Officer and director
GR
Ganesh Raj
Executive officer and director

Sources

  1. SECEtiraRX, Inc. filing history
  2. Companyetira contact